A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 312 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Mortality Trends for Most Cancers Remain Favourable In the EU, Although... January 27, 2026 FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma June 3, 2024 GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... February 2, 2021 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Load more HOT NEWS Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... Physical Activity May Lessen the Effects of Chemobrain, Study Finds FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia
